HSC Exam Practice

Sample response. Epidemiology is the study of patterns of disease and exposure across whole populations, including how disease is distributed and which factors are associated with higher risk. Its output is evidence rather than treatment: it identifies risk factors and disease patterns that the health system can act on, but it does not itself treat any individual patient.

Marking notes. 1 mark for defining epidemiology at the population level (patterns and distribution of disease, not individual diagnosis). 1 mark for identifying the output as evidence about risk factors or disease patterns rather than a treatment.

Sample response. Relative risk compares disease rates in exposed and unexposed groups, stating how many times more likely disease is in the exposed group. Attributable risk estimates the share of cases in a population that would be prevented if the exposure were removed. Attributable risk is more useful for setting a prevention budget, because it accounts for how common the exposure is as well as how much it raises risk. A relative risk of 1.3 for something as common as physical inactivity can generate far more preventable cases than a relative risk of 4.0 for a rare exposure.

Marking notes. 1 mark for a correct definition of relative risk. 1 mark for a correct definition of attributable risk. 1 mark for identifying attributable risk as the budget-setting measure with a reason referring to the prevalence of the exposure. Naming attributable risk without justification earns no third mark.

Sample response. First, the study produces a finding: a pattern or risk factor. Second, someone with the power to act converts that finding into a decision, such as a campaign, a screening program or a regulation. Third, the decision is implemented so that the target population can actually reach it. Fourth, new data check whether exposure, behaviour or disease rates changed. If any link breaks, the benefit shrinks to awareness only.

Marking notes. 1 mark for the first two links (finding and decision). 1 mark for implementation described as reaching the target population, not merely announcing. 1 mark for the outcome check. Award a bonus-eligible response only within the 3-mark cap; a list of four links without the "broken link" consequence still earns 3 if all four are correct.

Sample response. Any two, explained. The disease must be common and serious enough to matter at population scale, otherwise the cost and the harms of testing large numbers of well people outweigh the cases found. It must have a detectable early stage, so there is a window in which the test can identify it before symptoms appear. Early treatment must give a better outcome than late treatment, because detecting a disease earlier is pointless if the outcome is unchanged. The test must also be cheap and acceptable enough that people will actually take it.

Marking notes. 1 mark per condition correctly stated (maximum 2), plus 1 mark for explaining why at least one of them matters. A bare list of two conditions with no explanation earns 2 of 3.

Sample response. A national average conceals the distribution of the benefit. A program can report high overall uptake while uptake in remote communities, low-income groups or Aboriginal and Torres Strait Islander populations is less than half that figure. Those are frequently the groups carrying the greatest disease burden, so the response is reaching least the people who need it most. Because an intervention people cannot access produces awareness rather than health benefit, a defensible evaluation must report results disaggregated by region, income or Indigenous status to show whether the program is narrowing or widening the existing gap.

Marking notes. 1 mark for identifying that an average hides variation between groups. 1 mark for linking low access in a specific high-burden group to a reduced real benefit. 1 mark for stating the requirement for disaggregated reporting, or for the conclusion that an unequal program can widen the gap it set out to close.

Sample response. The studies first identified smoking as a strong, modifiable risk factor for lung cancer, rather than merely describing who developed the disease. That evidence then supported prevention through education and quit programs, and policy decisions including warning labels, advertising restrictions, taxation and smoke-free spaces, each of which reduced exposure across the whole population rather than one patient at a time. Prevalence and mortality patterns also guided service planning, showing where cessation services, screening and treatment resources were needed. Finally, later data showed smoking rates and then lung-cancer rates falling, which is the outcome check that turns an asserted benefit into an evaluated one. Because smoking accounts for roughly two in three lung-cancer deaths in Australia, its attributable risk is very high, which is why it justified this scale of response.

Marking notes. 1 mark for identification of a modifiable risk factor. 1 mark for prevention or policy actions named. 1 mark for service planning or resource allocation. 1 mark for the outcome check, that later data confirmed rates fell. Award the fourth mark alternatively for correct use of attributable risk to justify the scale of the response.

Sample response. Incidence, the number of new cases arising each year, falls gradually from about 13 to about 9 per 100,000 over the 20 years. Prevalence, the number of people living with treated end-stage kidney disease at any one time, more than doubles, rising from about 60 to about 135 per 100,000.

The two measures answer different questions. Incidence shows how fast fresh demand is arriving and is the correct measure for judging whether prevention and early detection are working; its fall suggests they are. Prevalence shows how many people currently require ongoing care and is the correct measure for sizing dialysis capacity, nursing hours and transplant places.

They move in opposite directions because better treatment keeps people alive longer on dialysis or after transplantation. Each year fewer people enter the treated population, but those already in it survive far longer, so the accumulated number needing continuous care grows even while new cases decline. Falling incidence with rising prevalence is therefore a sign of success on both fronts, not of prevention failing.

The proposal should be rejected as it stands. The manager has read the prevention measure and applied it to a service-capacity decision. Cutting the dialysis budget at the moment prevalence has more than doubled would reduce capacity precisely when demand is highest.

Additional data required: projected prevalence for coming years given current survival; current capacity utilisation and waiting times; transplantation rates, since transplant removes people from dialysis demand; mortality within the treated population; and rates disaggregated by remoteness and by Aboriginal and Torres Strait Islander status, because access barriers such as relocating for dialysis mean an average conceals which communities carry the burden.

Marking notes. 1 mark for correctly describing the incidence trend with values. 1 mark for correctly describing the prevalence trend with values. 1 mark for correctly stating what each measure is used to plan. 2 marks for explaining the divergence: 1 for improved survival or treatment, 1 for the accumulation logic. 1 mark for an explicit evaluation rejecting or heavily qualifying the proposal with justification. 1 mark for any two relevant additional data requirements.

Sample response outline. Position. Identifying a risk factor is a genuine first benefit because it shows where prevention could act, but the statement is too absolute: the benefit is realised only when the whole chain from finding to outcome holds.

Example 1, SunSmart and melanoma. Epidemiological work through the 1970s linked intermittent intense UV exposure and childhood sunburn to melanoma decades later. The evidence was strong, consistent and biologically plausible, since UV damages DNA in skin cells directly, which is why it justified action. The finding became decisions: the Slip Slop Slap campaign from 1981, no-hat-no-play rules, shade construction, workplace sun protection and UV-index reporting. The outcome check is the evaluation examiners reward: melanoma incidence in Australians under 40 has fallen while rates in older cohorts, exposed before the campaign, kept rising, a divergence matching the predicted exposure-to-disease lag and difficult to explain by any general cause.

Example 2, folate and neural tube defects. Studies showed low periconceptional folate raises neural tube defect risk, with a specific mechanism: folate supplies one-carbon groups for nucleotide synthesis, required for the rapid cell division that closes the neural tube within four weeks. Here the finding alone would have delivered almost nothing, because the critical window closes before most pregnancies are known, so advice arrives too late and cannot work at all for unplanned pregnancy. The benefit required a structural decision instead, mandatory folic acid fortification of bread-making flour from 2009. Follow-up data showed defect rates falling, with the largest falls in the highest-risk groups including teenage mothers and Aboriginal and Torres Strait Islander women.

Study quality. A benefit claim depends on the evidence being strong, consistent across studies and populations, temporally correct and biologically plausible. A single weak study confounded by other exposures rarely changes policy and should not, since acting on it wastes resources and credibility.

Access and equity. Evidence becomes benefit only through action people can reach. Sunscreen and shade cost money and screening needs transport and time away from work, so a campaign that raises awareness nationally while the highest-burden group cannot act on it produces a partial benefit and can widen the gap. The folate case is the contrast: fortification removed the need for individual action entirely, which is why its benefit was equitable by design.

Judgement. The statement is partly true and importantly incomplete. Identifying a risk factor is necessary but not sufficient. Epidemiology delivers its full benefit when reliable findings drive a decision that is implemented accessibly and then verified by outcome data, and the folate example shows that the form of the decision, structural rather than educational, can matter more than the strength of the finding.

Marking notes. 2 marks for two appropriate examples correctly described with their findings. 2 marks for the decisions and implementation each finding enabled. 1 mark for outcome evidence used to evaluate rather than assert benefit. 1 mark for study quality as a condition of benefit. 1 mark for equity or access treated as a determinant of real benefit. 1 mark for an explicit, qualified judgement on the statement.

Band guidance. Band 6 uses the benefit chain as an organising argument, contrasts the two examples deliberately and qualifies the statement precisely. Band 5 covers both examples and reaches a judgement but treats equity as an add-on. Band 4 describes two studies without evaluating whether benefit followed.